Summary: Chemical and Engineering News examines the challenges of obtaining licensing and funding for research into the potential benefits of psychedelics, highlighting organizations such as MAPS for completing and conducting multiple clinical trials involving psychedelics. “Pharmaceutical companies are generally uninterested in pursuing the compounds because their potential uses are already well-known, limiting companies’ ability to patent them and gain market exclusivity,” explains MAPS Founder and Executive Director Rick Doblin, Ph.D.
